CANNAINVESTOR Magazine March / April 2017 - Page 54

54

The 2017 Report “The Health Effects of Cannabis and Cannabinoids” by The National Academies of Science, Engineering, Medicine may prove to be ground-breaking. To download an uncorrected proof of the report (choose checkout as “guest” if you are not a member):

2017 Report - Health Effects. The final report in book form is also available for pre-order.

Modern research, development, and treatment may not be quite the same as navigating the same unchartered waters of developing new drugs and treatments from scratch. If marijuana were to be formally rescheduled for medical purposes, it just may be an Ecoforming event unparalleled on the pharmaceutical drug side. Much like the animal care sector, this may be another sector that the prepared Retail Investor could consider and the two sectors highlighted have a natural overlap. The cannabis plant may indeed pave the way for many new low cost drugs and treatments with few side effects that will not only be effective in treating the array of conditions we already know of but may also prove highly successful in other applications such as an effective alternate to antibiotics in some applications. But for now, it is academic speculation. Keeping current on such research may prepare the Retail Investor to short list companies to consider, The first five stocks listed on the February 2017 CANNAINVESTOR Magazine Top 25 Stock Picks List are all from the pharma sector. One such company - AbbVie Inc (NYSE:ABBV) is a producer of Marinol. Marinol (dronabinol) is presently the only US FDA-approved synthetic cannabinoid. The drug relieves nausea and vomiting in patients undergoing chemotherapy as well as to stimulate the appetite in AIDS patients. AbbVie Inc has had 45 years of consecutive dividend increases. Awareness of companies such as AbbVie Inc is just one example of the CANNAINVESTOR advantage.

The following table is just some of the reported medical applications for cannabis.